State of Wyoming Buys 6,418 Shares of AdaptHealth Corp. (NASDAQ:AHCO)

State of Wyoming boosted its stake in AdaptHealth Corp. (NASDAQ:AHCO) by 26.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 30,641 shares of the company’s stock after buying an additional 6,418 shares during the quarter. State of Wyoming’s holdings in AdaptHealth were worth $292,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Barclays PLC raised its holdings in shares of AdaptHealth by 361.3% in the third quarter. Barclays PLC now owns 181,240 shares of the company’s stock valued at $2,034,000 after purchasing an additional 141,949 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in AdaptHealth by 15.4% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,663 shares of the company’s stock worth $121,000 after purchasing an additional 1,690 shares in the last quarter. Blue Trust Inc. increased its stake in AdaptHealth by 24.1% in the 4th quarter. Blue Trust Inc. now owns 5,746 shares of the company’s stock valued at $55,000 after buying an additional 1,115 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in AdaptHealth in the 4th quarter valued at about $76,271,000. Finally, Empowered Funds LLC lifted its position in shares of AdaptHealth by 25.0% during the 4th quarter. Empowered Funds LLC now owns 713,643 shares of the company’s stock worth $6,794,000 after buying an additional 142,743 shares in the last quarter. 82.67% of the stock is currently owned by institutional investors.

AdaptHealth Price Performance

Shares of NASDAQ AHCO opened at $8.94 on Friday. The company has a current ratio of 1.24, a quick ratio of 1.00 and a debt-to-equity ratio of 1.34. The stock has a fifty day simple moving average of $9.10 and a two-hundred day simple moving average of $9.64. AdaptHealth Corp. has a 1-year low of $7.11 and a 1-year high of $11.90. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -5.42, a price-to-earnings-growth ratio of 1.08 and a beta of 1.64.

Wall Street Analyst Weigh In

AHCO has been the subject of several recent analyst reports. UBS Group reduced their target price on AdaptHealth from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Canaccord Genuity Group raised their target price on AdaptHealth from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Truist Financial lowered their target price on AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. Robert W. Baird increased their price target on shares of AdaptHealth from $14.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Finally, Royal Bank of Canada decreased their price objective on shares of AdaptHealth from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AdaptHealth currently has a consensus rating of “Buy” and a consensus price target of $13.40.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.